Genes that influence the development of adult T-cell leukemia

影响成人 T 细胞白血病发展的基因

基本信息

  • 批准号:
    10670414
  • 负责人:
  • 金额:
    $ 2.37万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1998
  • 资助国家:
    日本
  • 起止时间:
    1998 至 2000
  • 项目状态:
    已结题

项目摘要

The molecular mechanisms that influence the clinical development of adult T cell leukemia (ATL) are not fully understood. In the present study, we tried to identify the mRNA species that are differentially expressed in fresh peripheral blood mononuclear cells from patients with acute ATL and normal subjects, and MOLT-4. The ten genes ; tyrosine kinase Pyk2, JAK3, Tyk, Typo, HYL, Z225, MIP-lalpha, CD151, CCR7/EBI1, and CD70, were amplified preferentially in samples of PBMC from patients with acute ATL.Among these 10 genes, we further analyzed the role of CCR7/EBI1, Pyk2, and CD151 in pathogenesis of ATL.First, ATL cells from patients with lymphoid organ involvement expressed significantly more CCR7/EBI1 than normal T cells and ATL cells from patients without lymphoid organ involvement. This suggests that increased CCR7EBI1 expression plays a role in lymphoid organ infiltration of ATL cells. Second, Pyk2 was expressed higher in 6 freshly isolated ATL cells than in PBMC of normal subjects and MOLT-4. The Pyk2-transfected SF-HT clones grew without IL-2, while control vector-transfected SF-HT cells did not grow. Therefore, these findings suggest that Pyk2 may play a role on the progression of ATL through T cell activation. Finally, the expression levels of CD151, α4β1 integrin, andα5β1 integrin on ATL cells from lymph nodes of lymphoma-type ATL patients were significantly higher than those on circulating ATL cells from leukemia-type ATL patients. This suggests that the increased expression of these integrins may contribute to lymphoma formation.
影响成人T细胞白血病(ATL)临床发展的分子机制尚不完全清楚。在本研究中,我们试图确定在急性ATL患者和正常人以及MOLT-4新鲜外周血单个核细胞中差异表达的mRNA种类。从急性ATL患者的PBMC中优先扩增出酪氨酸激酶PYK2、JAK3、Tyk、Typo、HYL、Z225、MIP-α、CD151、CCR7/EBI1和CD70等10个基因,进一步分析了CCR7/EBI1、PYK2和CD151在ATL发病中的作用。提示CCR7EBI1的高表达在ATL细胞的淋巴器官浸润中起一定作用。第二,在6个新鲜分离的ATL细胞中,Pyk2的表达高于正常人和MOLT-4的PBMC。PYK2基因转染的SF-HT克隆在没有IL-2的情况下生长,而对照载体转染的SF-HT细胞不生长。因此,这些发现提示,Pyk2可能通过T细胞活化在ATL的进展中发挥作用。CD151、α4β1整合素和α5β1整合素在淋巴瘤型ATL患者淋巴组织中的表达水平显著高于白血病患者外周血中的ATL细胞。这表明,这些整合素的表达增加可能有助于淋巴瘤的形成。

项目成果

期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nomura,T.and Hasegawa,H.: "Chemokines and anti-cancer immunotherapy : Anti-tumor effect of EBI1-ligand chemokine(ELC) and secondary lymphoid tissue chemokine(SLC)."Anticancer Research. 20. 4073-4080 (2000)
Nomura,T. 和 Hasekawa,H.:“趋化因子和抗癌免疫疗法:EBI1 配体趋化因子 (ELC) 和次级淋巴组织趋化因子 (SLC) 的抗肿瘤作用。”抗癌研究。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hasegawa, H., Kohno, M., Nomura, T., Sasaki, M., and Fujita, S.: "Protein-tyrosine kinase Pyk2 is involved in progression of adult T-cell leukemia"Biochemical and Biophysical Research Communications. (in press).
Hasekawa, H.、Kohno, M.、Nomura, T.、Sasaki, M. 和 Fujita, S.:“蛋白质酪氨酸激酶 Pyk2 参与成人 T 细胞白血病的进展”生物化学和生物物理研究通讯。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HASEGAWA Hitoshi其他文献

HASEGAWA Hitoshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HASEGAWA Hitoshi', 18)}}的其他基金

Change of coral reef environment caused by expansion of seagrass
海草扩张引起的珊瑚礁环境变化
  • 批准号:
    15K01170
  • 财政年份:
    2015
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of the method for efficient induction of human regulatory T cells and tolerogenic dendritic cells and application to therapy
高效诱导人调节性T细胞和耐受性树突状细胞方法的建立及其在治疗中的应用
  • 批准号:
    24591464
  • 财政年份:
    2012
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of the bioactive molecules that enhance the induction and suppressive properties of human regulatory T cells and application to therapy
增强人类调节性 T 细胞诱导和抑制特性的生物活性分子的分析及其在治疗中的应用
  • 批准号:
    21591282
  • 财政年份:
    2009
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of the immunoregulation through GPCR expressing in immunocompetent cells and therapy for the autoimmune diseases
阐明免疫活性细胞中 GPCR 表达的免疫调节及自身免疫性疾病的治疗
  • 批准号:
    19591168
  • 财政年份:
    2007
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Expression of chemokines and their receptors in GVHD target organs and therapeutic target
GVHD靶器官及治疗靶点中趋化因子及其受体的表达
  • 批准号:
    17591045
  • 财政年份:
    2005
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Ca-activated K channel as a new therapeutic target for vascular remodeling, and its expressional control mechanism
Ca激活K通道作为血管重塑新治疗靶点及其表达控制机制
  • 批准号:
    16590656
  • 财政年份:
    2004
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Therapy for collagen diseases by using chemokine antagonists
使用趋化因子拮抗剂治疗胶原疾病
  • 批准号:
    14570414
  • 财政年份:
    2002
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CORAL REEF MAPPING WITH REMOTE SENSING DATA
利用遥感数据绘制珊瑚礁地图
  • 批准号:
    08680618
  • 财政年份:
    1996
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Cellular genes induced by HTLV-1 in CD4+ T cells
CD4 T 细胞中 HTLV-1 诱导的细胞基因
  • 批准号:
    07670533
  • 财政年份:
    1995
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Molecular mechanism of membrane association of Bruton's Tyrosine Kinase
布鲁顿酪氨酸激酶膜缔合的分子机制
  • 批准号:
    10604872
  • 财政年份:
    2023
  • 资助金额:
    $ 2.37万
  • 项目类别:
Elucidating anti-angiogenic tyrosine kinase inhibitor-induced vascular dysfunction
阐明抗血管生成酪氨酸激酶抑制剂诱导的血管功能障碍
  • 批准号:
    10570393
  • 财政年份:
    2023
  • 资助金额:
    $ 2.37万
  • 项目类别:
Receptor tyrosine kinase signaling in astrocyte migration and angiogenesis
星形胶质细胞迁移和血管生成中的受体酪氨酸激酶信号传导
  • 批准号:
    10734124
  • 财政年份:
    2023
  • 资助金额:
    $ 2.37万
  • 项目类别:
Tuning tyrosine kinase signalling to improve haematopoietic stem cell expansion and bone marrow transplantation
调节酪氨酸激酶信号传导以改善造血干细胞扩增和骨髓移植
  • 批准号:
    2889841
  • 财政年份:
    2023
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Studentship
The multifaceted role of c-Src tyrosine kinase in breast cancer progression.
c-Src 酪氨酸激酶在乳腺癌进展中的多方面作用。
  • 批准号:
    468470
  • 财政年份:
    2022
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Operating Grants
Enhancing Anti-Cancer Immunotherapy by Disruption of the non-Receptor Tyrosine Kinase Fes
通过破坏非受体酪氨酸激酶 Fes 增强抗癌免疫治疗
  • 批准号:
    476093
  • 财政年份:
    2022
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Studentship Programs
Receptor Tyrosine Kinase Transactivation in Neuronal Signalling, Stress, and Survival
受体酪氨酸激酶反式激活对神经元信号传导、应激和生存的影响
  • 批准号:
    RGPIN-2019-04177
  • 财政年份:
    2022
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Discovery Grants Program - Individual
Design and Synthesis of Novel Action Inhibitors for Bruton's Tyrosine Kinase (BTK)
布鲁顿酪氨酸激酶 (BTK) 新型作用抑制剂的设计与合成
  • 批准号:
    2751540
  • 财政年份:
    2022
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Studentship
Investigating Resistance Mechanisms to Non-covalent Bruton's Tyrosine Kinase Inhibitors and Therapeutic Approaches to Overcome Resistance for Patients with B-Cell Malignancies
研究非共价布鲁顿酪氨酸激酶抑制剂的耐药机制以及克服 B 细胞恶性肿瘤患者耐药性的治疗方法
  • 批准号:
    10537252
  • 财政年份:
    2022
  • 资助金额:
    $ 2.37万
  • 项目类别:
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
重新利用布鲁顿酪氨酸激酶 (BTK) 抑制剂来逆转高级别浆液性卵巢癌 (HGSC) 的免疫抑制
  • 批准号:
    10661823
  • 财政年份:
    2022
  • 资助金额:
    $ 2.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了